Gregory Frost
Director
biotechnology
BioAtla
China
Biography
Dr. Frost has been Managing Director of F1 BioVentures, LLC since 2015. Previously, he led the Health Sector of Intrexon Corporation, a multinational public biotechnology company, where he was responsible for expanding their oncology franchise and gene and cellular-based therapies for a number of orphan diseases. From 1999 to 2014, Dr. Frost was at Halozyme Therapeutics, a San Diego public biotechnology company he co-founded that focused on oncology biologics and medication delivery. At Halozyme he served on the Board of Directors and in numerous operational roles including Chief Scientific Officer since 2002, and CEO since 2010. He has authored multiple peer-reviewed and invited scientific articles, and is an inventor on key patents supporting a number of FDA approved biologics. Dr. Frost is a member of the American Society of Clinical Oncology, the American Association for Cancer Research and is registered to practice before the U.S. Patent and Trademark Office. Dr. Frost earned his B.A. in Biochemistry
Research Interest
biotechnology
